Drug Profile

Blarcamesine - Anavex Life Sciences

Alternative Names: AE-37 hydrochloride; ANA001-HCl; ANAVEX 2-73; Blarcamesine hydrochloride - Anavex Life Sciences

Latest Information Update: 29 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Anavex Life Sciences
Developer Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
Class Antidementias; Antidepressants; Antiepileptic drugs; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Biphenyl compounds; Dimethylamines; Furans; Neuroprotectants; Nootropics; Small molecules; Vascular disorder therapies
Mechanism of Action Muscarinic receptor modulators; Sigma-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Fragile X syndrome; Rett syndrome; Infantile spasms
New Molecular Entity Yes

Preregistration Alzheimer's disease
Phase III Rett syndrome
Phase II/III Fragile X syndrome; Unspecified
Phase II Parkinson's disease
Phase I Angelman syndrome
No development reported Infantile spasms
Discontinued Amyotrophic lateral sclerosis; Anxiety disorders; Autistic disorder; Cognition disorders; Multiple sclerosis; Stroke

18 Dec 2025 Anavex Life Sciences requests the European Medicines Agency (EMA) to re-examine its opinion on Blarcamesine for the treatment of Alzheimer's disease (Early-stage disease)
12 Dec 2025 The Committee for Medicinal Products for Human Use of EMA adopts a negative opinion on the marketing authorisation application for blarcamesine for he treatment of Alzheimer’s disease (Early-stage disease) in European Union
14 Nov 2025 Anavex Life Sciences received negative trend vote on the Marketing Authorisation Application (MAA) for blarcamesine following its CHMP oral explanation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com